FDA approves Progenics' drug for rare tumors

The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy

July 31, 2018

The U.S. Food and Drug Administration (FDA) have approved the New Drug Application for Progenics Pharmaceuticals' azedra, a treatment for two types of rare adrenal gland tumors. This approval makes it the first drug approved in the United States for this purpose.

According to the FDA, the med is now able to treat patients older than 2 who have either pheochromocytoma or paraganglioma tumors and require anti-cancer therapy.

The regulator said the drug would be used to treat patients whose tumor has spread beyond the original site and cannot be surgically removed.

Read the full news release